Cargando…
Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664342/ https://www.ncbi.nlm.nih.gov/pubmed/33285314 http://dx.doi.org/10.1016/j.leukres.2020.106473 |
| _version_ | 1783609825286946816 |
|---|---|
| author | Pelcovits, Ari Pandita, Aakriti Farmakiotis, Dimitrios Egan, Pamela |
| author_facet | Pelcovits, Ari Pandita, Aakriti Farmakiotis, Dimitrios Egan, Pamela |
| author_sort | Pelcovits, Ari |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7664342 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76643422020-11-16 Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR Pelcovits, Ari Pandita, Aakriti Farmakiotis, Dimitrios Egan, Pamela Leuk Res Letter to the Editor Elsevier Ltd. 2021-01 2020-11-13 /pmc/articles/PMC7664342/ /pubmed/33285314 http://dx.doi.org/10.1016/j.leukres.2020.106473 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Pelcovits, Ari Pandita, Aakriti Farmakiotis, Dimitrios Egan, Pamela Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title | Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title_full | Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title_fullStr | Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title_full_unstemmed | Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title_short | Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR |
| title_sort | lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive sars-cov-2 pcr |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664342/ https://www.ncbi.nlm.nih.gov/pubmed/33285314 http://dx.doi.org/10.1016/j.leukres.2020.106473 |
| work_keys_str_mv | AT pelcovitsari lymphocytedepletingchemotherapyforaggressivehematologicmalignanciesintwopatientswithpositivesarscov2pcr AT panditaaakriti lymphocytedepletingchemotherapyforaggressivehematologicmalignanciesintwopatientswithpositivesarscov2pcr AT farmakiotisdimitrios lymphocytedepletingchemotherapyforaggressivehematologicmalignanciesintwopatientswithpositivesarscov2pcr AT eganpamela lymphocytedepletingchemotherapyforaggressivehematologicmalignanciesintwopatientswithpositivesarscov2pcr |